Oncolytics Biotech regains compliance with Nasdaq listing requirements

SAN DIEGO/CALGARY - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a $34.64 billion market cap company, has regained compliance with Nasdaq’s minimum bid price requirement, according to a formal notice received Tuesday from the exchange’s Listing Qualifications Department.

The clinical-stage immunotherapy company had been notified on February 13, 2025, that it failed to maintain the required minimum bid price of $1.00 over 30 consecutive business days, as stipulated by Nasdaq Listing Rule 5550(a)(2).

According to the compliance notice, Oncolytics resolved the issue after its common shares maintained a closing bid price at or above $1.00 for 10 consecutive business days, from July 8 through July 21, 2025. The stock has shown remarkable momentum, gaining over 8% in the past week and trading near its 52-week high of $300. InvestingPro data reveals 12 additional key performance indicators for the stock.

The company is now in compliance with all Nasdaq listing standards and will continue trading on the Nasdaq Capital Market under the ticker "ONCY."

Oncolytics Biotech develops pelareorep, an intravenously delivered immunotherapeutic agent that has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer. Both indications have received Fast Track designation from the FDA. While currently not profitable, analysts tracked by InvestingPro expect the company to achieve profitability this year, with a strongly bullish consensus recommendation.

The information in this article is based on a press release statement from Oncolytics Biotech.

In other recent news, BeOne Medicines has garnered attention with several analyst updates and strategic developments. RBC Capital raised its price target for BeOne Medicines to $349, maintaining an Outperform rating, citing the company’s leadership in hematologic oncology and potential in solid tumors. Citizens JMP also reiterated a Market Outperform rating with a $348 price target, highlighting promising clinical data from BeOne’s R&D day, particularly for its Sonrotoclax + Zanubrutinib combination and BTK degrader BGB-16673. Additionally, RBC Capital reiterated its Outperform rating with a $311 price target, noting BeOne’s differentiated safety profile in its CDK4i program. Leerink Partners maintained an Outperform rating with a $334 price target, emphasizing BeOne’s robust portfolio of 30 clinical assets and 80 preclinical programs. Oncolytics Biotech reported significant survival benefits in cancer patients using its immunotherapy treatment pelareorep, with improved two-year survival rates for metastatic pancreatic ductal adenocarcinoma patients. The company also noted a 62% objective response rate when pelareorep was combined with chemotherapy and a checkpoint inhibitor. These developments reflect ongoing advancements and positive analyst sentiment in the biotechnology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.